Brief Title
Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis
Official Title
Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis
Brief Summary
Lung adenocarcinomas (LUADs) from Asian ancestry are reported to have different genomic architectures compared with LUADs from Caucasian ancestry. However, due to lack of available cases, few studies controlled the clinical attributes during the comparisons of the genomic alterations. In this study, the investigators will identify Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital. Then, Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) will be identified in the GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations. Finally, genomic alterations regarding somatic mutations, copy number variations, fusions, mutational signatures, oncogenic pathways, and therapeutic actionability will be comprehensively compared between these two cohorts after adjusting age, sex, smoking status, and pathologic stage using propensity score matching. This study will elucidate important ancestry differences between Asian and Caucasian lung adenocarcinoma patients.
Study Type
Observational
Primary Outcome
Oncoprint of somatic mutations
Condition
Adenocarcinoma of Lung
Study Arms / Comparison Groups
Asian lung adenocarcinoma
Description: Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
450
Start Date
January 2021
Completion Date
December 2021
Primary Completion Date
July 2021
Eligibility Criteria
Inclusion Criteria: - Primary lung adenocarcinoma - Broad-panel next-generation sequencing - Asian Exclusion Criteria: - Inadequate clinicopathological information - Low-quality next-generation sequencing
Gender
All
Ages
18 Years - 85 Years
Accepts Healthy Volunteers
No
Contacts
, 010-88326650, [email protected]
Administrative Informations
NCT ID
NCT04692935
Organization ID
2020PHB375
Responsible Party
Sponsor-Investigator
Study Sponsor
Jun Wang
Collaborators
Berry Genomics Co., Ltd.
Study Sponsor
, ,
Verification Date
January 2021